not much the company can do. I think they are doing everything they said they would do in terms of the product. its just the market for biotech and anything with a long gestation period such as this is being thrown in the bin.......maybe in time something will come out of it but its surely off to a very bad start at the very least!
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-6
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EBR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
0.040(3.85%) |
Mkt cap ! $332.7M | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.10 | $1.05 | $43.48K | 40.90K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 394 | $1.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 25808 | 2 |
View Market Depth
| Last trade - 16.10pm 02/07/2024 (20 minute delay) ? |
| EBR (ASX) Chart |